Introduction
Retinoic acid (RA) and interferon (IFN) (␣, ␤ or ␥) have supraadditive or synergistic differentiating, anti-proliferative, antiangiogenic and antiviral activities in various cell systems including those from human hematologic and solid tumors. [1] [2] [3] [4] [5] [6] Although, IFNs have no differentiation-inducing effects by themselves, their combination with RA potentiates the retinoid-induced differentiation in various cell lines. 2, 7 Both IFNs (␣, ␤, or ␥) and RA are known inhibitors of cell proliferation. In vitro and in vivo, their combination leads to a more potent growth inhibition. [6] [7] [8] [9] [10] [11] Recently, we have shown that in WISH, HL-60 and NB4 cells, RA inhibits vesicular stomatitis (VSV) replication. Treatment of these cells with RA and IFN-␣ combination afforded a stronger antiviral protection against VSV than with IFN alone. 6, 7 Thus, RA boosts the antiviral action of IFN. Combined RA-IFN effects have been correlated with the induction of higher levels of many IFN-stimulated gene (ISG) products. In various cell lines, RA increases the expression of the double-stranded protein kinase (PKR), the 2Ј5Ј oligoadenylate synthetase, PML, Sp100 and IRF-1; combined treatment with IFN results in a higher induction of these proteins compared to those induced by IFN alone. 6, 11, 12 In addition, in various cell lines, including those derived from acute promyelocytic leukemia (APL), RA increases directly the expression of transcription factors playing central roles in the mechanisms of IFN action. RA increases the expression of both signal transducer and activator of transcription, Stat1 and interferon regulatory factor, IRF-1. 6, [13] [14] [15] [16] [17] Additional mechanisms could be involved as RA also causes the induction and secretion of IFN-␣. 6, 7 This IFN seems to play a role in the inhibition of cell growth, facilitating RA-induced cell differentiation. 7 As a consequence of these events, RA enhances the IFN-induced STAT activation. Thus, the capacity of RA to increase the expression of STAT and IRF proteins and to induce IFN synthesis may be one of the molecular mechanisms mediating growth inhibition by RA and a crucial step in the enhancement of biological responses to IFN. In addition to IRF-1 and Stat1, p21 WAF/CIP1 is also co-regulated by both RA and IFNs. [18] [19] [20] A functional RARE has been identified in the p21 WAF/CIP1 promoter and is required to confer RA induction through RAR-RXR heterodimers. 20 The upregulation of the p21 WAF/CIP1 gene by IFNs and RA constitutes another example of a direct mechanism by which these two agents can synergize at the transcription level, in inducing both growth inhibition and cellular differentiation.
The in vivo and in vitro antitumor efficiency of IFNs is well documented. Their synergistic combination with RA in leukemic cell lines 1, 21 and in patients with squamous cell carcinomas 2, 22 are promising. From recent data, it becomes apparent how and at what level RA acts on IFN signaling leading to the amplification of IFN-induced biological activities. This may help in identifying new approaches in the therapy of cancer and in understanding the pathogenesis of APL.
IFN signaling and increase in gene expression
IFNs are a group of multifunctional cytokines that regulate cellular antiviral, anti-tumor and immunological responses [23] [24] [25] [26] through the expression of IFN-stimulated genes (ISGs). Production of IFN depends on the stimulus and the nature of the cell that is being stimulated. Human IFNs are classified as ␣, ␤, and ␥ on the basis of their antigenic properties. Type I IFNs (␣, ␤, ) are acid stable. IFNs of type I are induced in response to viral infection, double-stranded RNA treatment or other stimuli. [27] [28] [29] [30] IFN-␣ species and IFN-are products of leukocytes, whereas IFN-␤ is produced by fibroblasts. IFN-, another type I IFN, has been described only in ungulate species. 24 IFN-␥ (type II), which is acid labile, is induced in T lymphocytes and natural killer cells in response to antigens or mitogens. IFNs-␣/␤ and IFN-␥, after interacting with specific cell surface receptors, activate different signal cascades leading to the transcription of distinct set of genes which mediate the biological effects of these cytokines. 26, [31] [32] [33] [34] [35] The IFNs-␣/␤ and IFN-␥-inducible gene promoters are characterized by the presence of consensus elements, respectively, the IFN-stimulated response element (ISRE) and the IFN-␥-activated site (GAS). Binding of both IFNs-␣/␤ and IFN-␥ results in the differential activation of latent cytoplasmic factors, STATs, which act at different cis-acting DNA elements. Type I IFN-receptor interaction results in oligomerization of the receptor chains (ie the IFN-␣-occupied IFN-␣R2 associates with the IFN-␣R1 chain), which triggers a tyrosine phosphorylation cascade (Figure 1 ). Jak1 and Tyk2 phosphorylate Stat1, Stat2 and Stat3 leading to the formation of STAT homo-or heterodimers through mutual phosphotyrosine-Src homology region 2 (SH2) interactions. 31, 36 The IFN-stimulated gene factor 3 (ISGF3) is formed by Stat1 and Stat2 (Stat1:2) in association with the DNA-binding protein, p48, a member of the IRF family. 34, 37 Both ISGF3 and the complex between Stat1 homodimers and p48 bind to the ISRE. In addition, homo-and heterodimers of Stat1 and Stat3 (Stat1:1, Stat3:3 and Stat1:3) bind to a palindromic version of the GAS, regulating the expression of distinct ISGs. [38] [39] [40] IFN-␥ signaling require the obligatory participation of five distinct proteins: type I integral membrane receptor proteins, IFNGR1 (previously named the ␣ chain) and IFNGR2 (previously noted as the ␤ chain), Jak1, Jak2 and Stat1. 26 Functionally active IFN-␥ is a homodimer which binds to two IFNGR1 subunits, thereby generating binding sites for two IFNGR2 subunits (Figure 1 ). Activated Jak1 and Jak2 phosphorylate Stat1 which forms homodimers leading to its binding to the GAS motif ( Figure 1 ). The transcription factor IRF-1 which is highly induced by IFN-␥, because of the presence of a GAS site in its promoter, has the property to bind the ISRE directly activating IFN-␣/␤ stimulated genes. The characterization of these signalling pathways has provided some insights into the overlapping or synergistic effects of various IFNs.
More than 60 human proteins are known to be IFNinduced, but the physiological role of the majority has not been established yet. A few of the IFN-induced proteins were shown to have intrinsic antiproliferative and/or antiviral activities, namely the double-stranded protein kinase (PKR), 41 ,42 the 2Ј5Ј oligoadenylate synthetase, 43 certain Mx family proteins, 44 PML 45-50 and the 9-27 protein. 51 IFNs are effective therapy for malignancies. They have demonstrated broad applications in cancer as well as virologic diseases. IFN-␣ has beneficial therapeutic activity in non-metastatic melanoma, chronic myelogenous leukemia, B, T cell lymphoma and Kaposi's sarcoma. 24 Recent studies have demonstrated similar efficacy profiles for IFN-␣ currently approved for the treatment of chronic hepatitis C virus. 52 IFN-␤ has been shown to be efficient in the treatment of multiple sclerosis, 53 whereas IFN-␥ has been recognized as being effective in the prophylaxis of chronic granulomatous disease and as adjunctive treatment in at least one systemic intracellular infection, visceral leishmaniasis. 54 Additional trials suggest beneficial effects as prophylaxis in trauma and as treatment in leprosy, cutaneous leishmaniasis, and HIV-or non-HIV-related disseminated atypical mycobacterial infection. 54 Finally, IFNs-␣, ␤, and ␥ represent a promising antiviral modality that can be directed against all sites of human papillomavirus infection.
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RA signaling and activation of gene expression
Retinoids, a group of molecules derived from retinol (vitamin A), play various regulatory functions such as inhibition of proliferation and induction of differentiation not only in normal cells but also in tumors, such as teratocarcinomas and leukemias. [56] [57] [58] The prototype of these is the all-trans retinoic acid, a natural metabolite. In the cytosol, RA can bind to cytoplasmic RA binding proteins (CRABP), which regulate the distribution, the storage and metabolism of RA. After entering the nucleus, RA binds to specific nuclear receptors and modulates gene expression necessary for its biological functions. Two families of retinoid receptors have been described: retinoic acid receptor (RAR) and retinoid X receptor (RXR). Each receptor family includes three members ␣, ␤ and ␥. RA binds to a heterodimer of these two classes of receptors (RAR/RXR), which subsequently associate with RA response elements (RARE) to stimulate target gene expression. 59, 60 Three isomers, 13-cis-RA, all-trans-RA and 9-cis-RA, have been identified as ligands for RAR/RXR, whereas homodimerized RXRs bind to the 9-cis isomer with high affinity. 61 Clinically, retinoids have shown variable effectiveness in therapy and/or prevention of cancer of the following organs: skin, head and neck, lung, bladder, cervix, vulva, bone mar-row. 57, 62 The real success appears in acute promyelocytic leukemia (APL), 63, 64 where RA provides the first example of differentiation therapy, it can induce clinically complete remission through differentiation of the blast cells (see below). The mechanisms underlying the anti-carcinogenic activity of retinoids appear to be associated with their ability to modulate growth, differentiation, and apoptosis of normal, premalignant, and malignant cells in vitro and in vivo.
Effect of RA or IFNs on the Stat expression and activation
It has been recently shown that RA increases the level of Stat1 and Stat2 in various cell lines, WISH, U-937, HL-60 and NB4. 6, 13, 16, 17 Defective IFN signal transduction in malignant cells may be one reason for their resistance to the antiproliferative effect of IFN. Interestingly, by upregulating Stat1 expression in IFN-resistant breast tumor MCF-7 cells, RA is able to restore IFN sensitivity.
14 Thus, the increase of Stat1 level by RA may be important in the enhancement by this agent of biological responsiveness to IFNs. Moreover, the Stat1 promoter responds directly to RA treatment, a RARE was identified in the promoter region of the murine Stat1 gene. 65 Recent studies have shown that Stat1 mRNA is induced in the presence of cycloheximide by IFN of type I and II, 66 suggesting that in addition to the RARE, ISRE and GAS elements could also be present in this promoter. The human Stat2 gene promoter has a functional ISRE site 67 which could be responsive to IRF-1 or IFN-␣. Whether Stat2 is directly induced by RA remains to be elucidated.
It has also been shown that in cells pretreated with low doses of IFN-␥ and subsequently stimulated with IFN-␣, an enhanced formation of specific transcription factor complexes was detected probably due to higher levels of Stat1, Stat2 and p48. 66 The capacity of IFNs to induce the expression of these transcription factors could also explain the synergy observed in the different cell lines between type I and II IFNs.
We and others have shown that RA treatment from 30 min to 3 days of HL-60, WISH or NB4 cells never leads to Stat1 tyrosine phosphorylation as tested by GAS DNA-binding assays or Western blot analysis. 6, 7, 14 However, RA pretreatment of HL60, WISH or NB4 cells (for more than 1 day) significantly increases Stat1 activation in response to IFN-␣ and IFN-␥. 6, 7, 16 This suggests that higher intracellular levels of Stat1 due to RA treatment result in enhanced signal transduction for type I or type II IFNs. Recently, it has been shown that resistance to the growth inhibitory effect to IFN-␣ in cutaneous T cell lymphoma cell line is associated with a lack of Stat1 expression. 68 Pretreatment of such resistant cells with RA or IFN-␥ could increase Stat1 expression and restore IFN-␣ sensitivity.
Upregulation by RA or IFN of the transcription factors IRF
Interferon regulatory factors 1 and 2 (IRF-1 and IRF-2) were discovered as transcription activator and repressor molecules, respectively, of type I IFN, 69 and IFN-inducible genes. 72 Phosphorylation seems to be necessary for IRF-1 activity since DNA binding is inhibited by treatment with calf intestinal phosphatase. 70 Upon Sendai virus infection, cytoplasmic IRF-3 is phosphorylated and translocated into the nucleus 73 where it binds IFN-␣ and IFN-␤ promoters. 74 The expression of IRF-7 is restricted to lymphoid cell types and is inducible by viral infection or IFN-␣ treatment. Overexpression of IRF-7 results in activation of IFN-␣ promoter and a strong enhancement of virus-mediated activation of this promoter. 75 Different studies reported that RA induces IRF-1 gene expression in NB4 cells after a short period of treatment and in the absence of protein synthesis. 13, 15 We have shown that RA stimulates IRF-1 gene expression with the same efficiency as IFN-␣. 6 The GAS motif, 40 which mediates the induction of IRF-1 in response to IFNs, seems to be the main RA responsive element in the IRF-1 promoter. 6 In addition to the GAS site, a putative NF-B site has been found in the IRF-1 gene promoter. 76 IFN-␥ and TNF synergistically increase IRF-1 gene expression through the activation of Stat1 and NF-B transcription factors, respectively. 77, 78 However, in NB4 cells, RA alone did not induce directly any detectable Stat1 7, 15 or NF-B 15 DNA binding activities, suggesting that these factors are not implicated in RA-induced IRF-1 gene expression.
Another member of the IRF family, the p48 protein, is also upregulated by RA. 7, 13, 16, 17 Kinetic studies revealed that in RAtreated NB4 cells, IRF-1 induction precedes that of p48. 7 Whether p48 is transcriptionally regulated, like IRF-1, by RA remains to be studied.
RA induces IFN-␣ synthesis
RA causes the induction of IFN in HL-60 and NB4 cells. 6, 7 This IFN has been characterized as IFN-␣ because anti-human IFN-␤ or IFN-␥ antibodies did not alter its antiviral activity, whereas anti-human IFN-␣ antibodies abolished it totally. RAinduced IFN seems to play a role in the inhibition of NB4 cell proliferation 7 which could facilitate their differentiation. How RA induces IFN synthesis remains to be elucidated. IRF-3 seems not to be implicated in IFN induction by RA. Indeed, IRF-3 is phosphorylated in NB4 cells after Sendai virus infection and not after RA treatment. 7 It is unlikely that ISGF3 is formed after RA treatment and responsible for IFN induction, because RA is unable to stimulate tyrosine phosphorylation of Stat1. 6, 7, 15 Expression of IRF-1 alone is not sufficient to induce IFN synthesis (see below). Studies are in progress to elucidate whether other members of the IRF family are implicated in this phenomenon.
Acute promyelocytic leukemia: effects of IFNs and RA
RA is a strong cyto-differentiating agent efficient in the clinical treatment of acute promyelocytic leukemia (APL), the M3 subtype in the French-American-British (FAB) classification. 64, 79 APL is characterized by a developmental arrest of granulopoiesis at the promyelocytic stage. This pathology is associated with the t(15;17) translocation that causes the formation of the PML/RAR␣ and RAR␣/PML fusion genes, which are transcriptionally active and encode PML-RAR␣ and RAR␣-PML fusion proteins; PML/RAR␣ fusion transcripts (under the control of the PML promoter) and proteins are found in all APL patients whereas RAR␣-PML fusion transcripts are detected in the majority but not all APL patients. 80 The PML-RAR␣ fusion protein contains the functional domains of both PML and RAR␣ and is the likely molecular basis of APL leukemogenesis probably by altering PML and/or RAR␣ functions. Transgenic mice studies showed that expression of PML-RAR␣ resulted in altered myelopoiesis and development of leukemia indicating a crucial role of the fusion protein in leukemogenesis. 81, 82 In normal cells, PML has a speckled nuclear pattern of expression which is the consequence of its localization to poorly characterized nuclear organelles named nuclear bodies (NBs). [83] [84] [85] [86] PML colocalizes on NBs with primary biliary cirrhosis autoantigens such as Sp100. 87 In APL, both the PML and Sp100 patterns are dominantly delocalized by the PML-RAR␣ fusion protein towards distinct microspeckles which are smaller and much more numerous. [84] [85] [86] The PML-RAR␣ fusion protein may form heterodimers with PML and RXR and could behave as a dominant negative inhibitor of PML and RXR. 88 Furthermore, the sequestration of RXR by PML-RAR␣ may impair the heterodimerization of RXR with some hormone receptors like RAR, thyroid hormone receptor or vitamin D3 receptor 89, 90 and therefore could result in a differentiation arrest.
NB4, the only known cell line bearing the t(15;17) translocation 91 which, at one and the same time, is characterized by a promyelocytic morphology, sensitivity to the differentiating, antiproliferative and pro-apoptotic actions of RA.
IFN-␣ or IFN-␥ treatment of NB4 cells results in an increase of many ISGs as well as inhibition of cell growth and viral replication. 7, 10, 13 In addition, both IFN types induce the expression of the chimeric protein PML-RAR␣, 45, 92 this because PML, like Sp100, 93 is a primary target gene of IFN. Its promoter contains the ISRE and GAS elements. 94 IFN-␣ or IFN-␥ treatment resulted in an increase of the abnormal microspeckled localization pattern of PML, Sp100 and PML-RAR␣. 45 The IFN-induced PML/RAR␣ is accompanied by an enhanced sequestration of its heterodimeric partner RXR. As mentioned above, in APL cells, RA induces Stat1, Stat2, p48 and IRF-1 expression as well as IFN␣ synthesis. In addition, differentiation of APL cells by RA is accompanied by proteolytic degradation of PML-RAR protein resulting in restoration of the normal nuclear PML localization on NBs. [84] [85] [86] 95 Downregulation of the chimeric protein occurs at the post-translational level and is prevented by proteasome 95 or caspase inhibitors.
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RA-derivative resistant cells, a model to understand RA and IFN crosstalk
One of the main problems in APL treatment is the appearance of retinoids resistance. 97 The molecular mechanisms responsible for this RA insensitivity are still unclear although several possible mechanisms have been considered. One could be due to acquired mutations in the RA receptors. It has been shown that HL-60 myeloid cells are rendered unresponsive to the differentiating activity of RA by a mutation in the RAR␣ gene;
98 the resistance is overcome by transfecting the wildtype RAR␣ cDNA. 99 Another potential mechanism for clinical RA resistance consists of pharmacological alterations in the metabolism of RA. Continuous treatment with RA in APL is associated with a progressive reduction of the plasma concentration of RA. These lower plasma and cellular levels of active retinoids 97 result from induction of cytochrome P-450, cellular RA-binding protein (CRABP) and P-glycoprotein. Interestingly, IFN-␣ is known to downregulate cytochrome P450-dependent mono-oxygenases. 100 Two distinct types of maturation-deficient NB4 cell sublines, NB4-R1 and NB4-R2, were isolated from the RA-sensitive parental cells. 101 RA alone is unable to induce maturation and to inhibit cell growth of these resistant cells. 102 It has been shown that the basal level of RAR␣, RXR␣ and PML mRNAs as well as the corresponding proteins were roughly the same in the three cell lines. 103 While NB4, NB4-R1 and NB4-R2 cells express comparable amounts of PML-RAR␣ mRNA, only NB4 and NB4-R1 cells express the chimeric protein. In NB4-R1 cells, RA-induced PML-RAR␣ decrease is associated with changes in surface markers but not terminal maturation. 103 As suggested previously, 104 in RA-resistant cells, induction of PML-RAR␣ degradation may be a first step but not sufficient for the full response to RA.
NB4-R1 cells treated with low doses of RA fail to mature, although they respond to RA since they can be subsequently triggered to maturation by an additional cAMP signal (cAMP alone is inactive).
101 NB4-R2 cells were resistant to the combined RA and cAMP treatment. In the parental NB4 cells, RA and cAMP act synergistically to induce maturation. 105 Relatively little is known about the RA target genes which are involved in regulating cell proliferation and differentiation. We have shown that RA resistance in NB4 APL cells is associated with lack of IFN-␣ synthesis, Stat1, p48 and p21 . IRF-1 and p48 proteins are also highly induced in NB4 cells, but the fate of these two proteins upon RA treatment is different in the resistant cell lines. In NB4-R1 and NB4-R2 cells, the induction of p48 by RA was totally blocked, while IRF-1 mRNA and protein levels increased in both NB4-R1 and NB4-R2 cells. In addition, in NB4 cells, RA induces the synthesis and the secretion of IFN-␣ with a titer value of 256 IU/ml. 7, 17 In contrast, no detectable IFN activity was found in supernatants from RA-treated resistant cells NB4-R1 and NB4-R. 7 Upon RA treatment for 3 days, PKR and Sp100 were highly induced in NB4 cells but not affected in the two resistant cells, confirming that IFN is only induced in the parental cell line (Figure 2 ). The comparison of kinetic studies clearly shows that RA-induced IRF-1 expression in NB-4 cells precedes IFN-␣ secretion. However, in resistant cells, RA is still able to induce IRF-1 mRNA and protein expressions in the absence of detectable IFN secretion and without any inhibition of cell growth. 7 Thus, in this system, increase of IRF-1 expression by RA is not sufficient to induce IFN synthesis and to inhibit the growth of these cells. However, we cannot exclude that in parental NB4 cells, RA induces IRF-1 activation which could be impaired in the resistant cells.
In NB4, NB4-R1 and NB4-R2 cells, IFN-␣ or -␥ similarly increased the expression of PKR, Sp100 and Stat1, inhibited their growth and induced Stat1 activation 7 suggesting that the main IFN pathways are functional in the three cell lines. Also, RA pretreatment of NB4 cells did significantly increase Stat1 activation in response to IFN-␣ and IFN-␥ 7,15 thus increasing expression of different IFN-stimulated genes and enhancing diverse biological activities such as differentiation, inhibition of cell or virus growth. 7, 10 In contrast, priming both resistant cells for 3 days with RA had no effect in increasing Stat1 activation by IFN-␣ or IFN-␥. 7 Consequently, RA was unable to enhance IFN-induced biological activities, probably due to the absence of IFN synthesis and increase of Stat1 expression.
Conclusions
Taken together, these results lead us to propose a model for activation of IFN-stimulated genes by RA (Figure 3) . One of the primary events is the direct induction of IRF-1 gene expression. As RA is not able to induce tyrosine phosphorylation, it may enhance STAT activity through, for instance, the activation of MAP kinases which have been shown to modulate STAT activation. 106 De novo synthesized IRF-1 directly activates a variety of IFN-inducible genes and the IFN-␣ gene itself, leading to a positive feedback on IRF-1 expression. Other unknown factors could be implicated in the induction of IFN-␣ by RA. In the long-term, RA also increases STAT levels, which could be activated by the RA-induced IFN-␣. Moreover, exogeneous IFN could also enhance, in the short or long term, the activation of STAT.
Several recent studies have shown that combination therapy with RA and IFN is very effective in treating some forms of cancer. These findings can be explained by the crosstalk between RA and IFN, ie RA induces IFN-␣ synthesis and directly increases the expression of the transcription factors Stat1 and IRF-1 playing key roles in IFN-specific signaling. Activation by IFNs of signal transduction from the cell surface receptor via the Jak-Stat pathway is an early obligatory event in inducing ISG products mediating IFN biological effects. In addition to IRF-1 and Stat1, p21 WAF/CIP1 is also co-regulated by both RA and IFNs. [18] [19] [20] The upregulation of the p21 WAF/CIP1
gene by IFNs and RA represents another example of a direct mechanism by which these two agents can synergize at the transcription level, thus contributing to higher cellular differentiation and growth inhibition. Tumor cells may have evolved mechanisms that inhibit functions of growth suppressive cytokines such as IFNs. Interestingly by upregulating Stat1 expression in IFN-resistant breast tumors, RA is able to restore IFN sensitivity.
14 The finding that RA inhibits virus replication and in combination with IFN, boosts the antiviral activity of this cytokine 6 suggests that the combination therapy could be extended to other diseases. The effectiveness of IFN-␣ alone in APL could be controversial because the oncogenic PML-RAR␣ is under the transcriptional control of IFN. 94 In principle, increased levels of the chimeric protein may cause an acceleration of the disease. In vitro, IFN and RA potentiate each other to inhibit cell growth and to induce differentiation, thus clearly overcoming the PML-RAR␣ effect. Recently, it has been shown that RA and arsenic synergize to eradicate leukemic cells in a mouse model of APL. 107 Such a model tests the efficacy of RA and IFN combination in vivo.
